Changjiang Pharmaceutical Group Co., Ltd. (SHE:300391)
China · Delayed Price · Currency is CNY 0.9200
+0.1500 (19.48%)
At close: Jan 23, 2026
SHE:300391 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 112.44 | 108 | 1,189 | 1,610 | 2,348 | 1,203 |
Other Revenue | 3.63 | 3.63 | 8.15 | 5.54 | 13.76 | 11.86 |
| 116.07 | 111.63 | 1,198 | 1,615 | 2,362 | 1,215 | |
Revenue Growth (YoY) | -58.05% | -90.68% | -25.86% | -31.61% | 94.48% | 67.45% |
Cost of Revenue | 128.78 | 120.18 | 1,026 | 1,288 | 1,834 | 953.91 |
Gross Profit | -12.7 | -8.56 | 171.2 | 327.3 | 527.79 | 260.59 |
Selling, General & Admin | 119.01 | 114.33 | 104.61 | 134.85 | 201.83 | 145.24 |
Research & Development | 6.92 | 7.9 | 7.66 | 25.76 | 39.36 | 43.16 |
Other Operating Expenses | 2.7 | 2.46 | 3.71 | 6 | -10.28 | -2.51 |
Operating Expenses | 780.58 | 752.65 | 309.67 | 244.95 | 276.65 | 181.83 |
Operating Income | -793.28 | -761.21 | -138.48 | 82.36 | 251.14 | 78.76 |
Interest Expense | -79.88 | -111.17 | -61.31 | -56.03 | -37.95 | -15.56 |
Interest & Investment Income | 1.69 | 0.06 | 0.1 | 55.56 | 0.85 | 2.06 |
Currency Exchange Gain (Loss) | 0.81 | 0.81 | 0.43 | 5.71 | -0.38 | -3.68 |
Other Non Operating Income (Expenses) | -1.26 | -6.48 | -2.03 | 20.21 | -22.35 | -13.48 |
EBT Excluding Unusual Items | -871.92 | -877.99 | -201.29 | 107.81 | 191.32 | 48.1 |
Impairment of Goodwill | -219.7 | -219.7 | -439.36 | -26.31 | - | - |
Gain (Loss) on Sale of Investments | -4.39 | -4.39 | 67.63 | - | -1.05 | -2.46 |
Gain (Loss) on Sale of Assets | -0.46 | -0.3 | 0.08 | 0.05 | 2.1 | -3.29 |
Asset Writedown | -203.39 | -230.53 | -107.58 | -15.54 | -16 | -0.08 |
Legal Settlements | -1.04 | -1.04 | -0.84 | - | - | - |
Other Unusual Items | -93.37 | -93.75 | 0.35 | 5.82 | -18.04 | 16.14 |
Pretax Income | -1,394 | -1,428 | -681.01 | 71.83 | 158.32 | 58.41 |
Income Tax Expense | 10.55 | 10.96 | 26.32 | 27.25 | -1.01 | -7.88 |
Earnings From Continuing Operations | -1,405 | -1,439 | -707.33 | 44.57 | 159.33 | 66.29 |
Minority Interest in Earnings | 748.11 | 810.71 | 101.68 | -67.85 | -110.23 | -40.97 |
Net Income | -656.72 | -627.96 | -605.65 | -23.27 | 49.1 | 25.32 |
Net Income to Common | -656.72 | -627.96 | -605.65 | -23.27 | 49.1 | 25.32 |
Net Income Growth | - | - | - | - | 93.94% | - |
Shares Outstanding (Basic) | 350 | 350 | 350 | 351 | 350 | 350 |
Shares Outstanding (Diluted) | 350 | 350 | 350 | 351 | 350 | 350 |
Shares Change (YoY) | 0.00% | -0.00% | -0.05% | 0.07% | 0.01% | -0.04% |
EPS (Basic) | -1.87 | -1.79 | -1.73 | -0.07 | 0.14 | 0.07 |
EPS (Diluted) | -1.87 | -1.79 | -1.73 | -0.07 | 0.14 | 0.07 |
EPS Growth | - | - | - | - | 93.91% | - |
Free Cash Flow | -175.26 | -79.51 | -154.22 | -117.55 | 88.72 | 13.98 |
Free Cash Flow Per Share | -0.50 | -0.23 | -0.44 | -0.34 | 0.25 | 0.04 |
Gross Margin | -10.94% | -7.66% | 14.29% | 20.26% | 22.35% | 21.46% |
Operating Margin | -683.43% | -681.93% | -11.56% | 5.10% | 10.63% | 6.49% |
Profit Margin | -565.78% | -562.56% | -50.57% | -1.44% | 2.08% | 2.08% |
Free Cash Flow Margin | -150.99% | -71.23% | -12.88% | -7.28% | 3.76% | 1.15% |
EBITDA | -766.08 | -729.98 | -101.88 | 186.37 | 308.75 | 121.75 |
EBITDA Margin | - | - | -8.51% | 11.54% | 13.07% | 10.02% |
D&A For EBITDA | 27.2 | 31.23 | 36.6 | 104.01 | 57.6 | 42.98 |
EBIT | -793.28 | -761.21 | -138.48 | 82.36 | 251.14 | 78.76 |
EBIT Margin | - | - | -11.56% | 5.10% | 10.63% | 6.49% |
Effective Tax Rate | - | - | - | 37.94% | - | - |
Revenue as Reported | 116.07 | 111.63 | 1,198 | 1,615 | 2,362 | 1,215 |
Advertising Expenses | - | 0.82 | 0.89 | 0.09 | 0.79 | 0.79 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.